DermBiont

DermBiont is a biotechnology company developing microbial therapeutics for the treatment of skin diseases. Its pipeline of topical therapeutic candidates includes DBI-001 for eczema, athlete’s foot, and nail fungus; DBI-002 for inflammatory dandruff; and SM-020 for benign skin tumors. By harnessing naturally occurring microbial communities, DermBiont aims to address the underlying microbial imbalances that contribute to common dermatological conditions, offering alternatives to traditional steroid and antifungal treatments. Founded in 2015 and headquartered in Melrose, Massachusetts, the company has raised approximately $78.9 million in Series B funding from investors including Zola Global, Toba Capital, Viking Global Investors, Civilization Ventures, Illumina, Pivotal bioVenture Partners, Joyance Partners, and Massachusetts Biomedical Initiatives.